Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rami S Komrokji

Showing results (1-10 of 204) with videos related to

Pageof 21
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Current State of the Art: Management of Higher Risk Myelodysplastic SyndromesRami S Komrokji
Current Hematologic Malignancy Reports|June 17, 2019
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDSRami S Komrokji
Hematology/Oncology Clinics of North America|February 25, 2020
Luspatercept in Myelodysplastic Syndromes: Who and When?Rami S Komrokji
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating AgentsRami S Komrokji
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic SyndromesRami S Komrokji
Future Oncology (London, England)|September 15, 2015
A comprehensive review of pacritinib in myelofibrosisSrdan Verstovsek, Rami S Komrokji
Expert Review of Hematology|October 30, 2014
Novel and emerging therapies for the treatment of polycythemia veraSrdan Verstovsek, Rami S Komrokji
Future Oncology (London, England)|January 29, 2021
Luspatercept in the treatment of lower-risk myelodysplastic syndromesOnyee Chan, Rami S Komrokji
Current Opinion in Hematology|January 27, 2007
Evolving classifications of the myelodysplastic syndromesRami S Komrokji, John M Bennett
Current Hematologic Malignancy Reports|August 28, 2013
There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromesAmer M Zeidan, Rami S Komrokji
Pageof 21

Showing results (1-10 of 204) with videos related to

Sort By:
Pageof 21
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Current State of the Art: Management of Higher Risk Myelodysplastic SyndromesRami S Komrokji
Current Hematologic Malignancy Reports|June 17, 2019
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDSRami S Komrokji
Hematology/Oncology Clinics of North America|February 25, 2020
Luspatercept in Myelodysplastic Syndromes: Who and When?Rami S Komrokji
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating AgentsRami S Komrokji
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic SyndromesRami S Komrokji
Future Oncology (London, England)|September 15, 2015
A comprehensive review of pacritinib in myelofibrosisSrdan Verstovsek, Rami S Komrokji
Expert Review of Hematology|October 30, 2014
Novel and emerging therapies for the treatment of polycythemia veraSrdan Verstovsek, Rami S Komrokji
Future Oncology (London, England)|January 29, 2021
Luspatercept in the treatment of lower-risk myelodysplastic syndromesOnyee Chan, Rami S Komrokji
Current Opinion in Hematology|January 27, 2007
Evolving classifications of the myelodysplastic syndromesRami S Komrokji, John M Bennett
Current Hematologic Malignancy Reports|August 28, 2013
There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromesAmer M Zeidan, Rami S Komrokji
Pageof 21